ATE187329T1 - Carnitinderivat als arzneimittel zur behandlung von arteriosklerose obliterans - Google Patents

Carnitinderivat als arzneimittel zur behandlung von arteriosklerose obliterans

Info

Publication number
ATE187329T1
ATE187329T1 AT96830093T AT96830093T ATE187329T1 AT E187329 T1 ATE187329 T1 AT E187329T1 AT 96830093 T AT96830093 T AT 96830093T AT 96830093 T AT96830093 T AT 96830093T AT E187329 T1 ATE187329 T1 AT E187329T1
Authority
AT
Austria
Prior art keywords
treatment
arteriosclerosis obliterans
medicinal product
carnitine derivative
carnitine
Prior art date
Application number
AT96830093T
Other languages
English (en)
Inventor
Marco Corsi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE187329T1 publication Critical patent/ATE187329T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT96830093T 1996-03-04 1996-03-04 Carnitinderivat als arzneimittel zur behandlung von arteriosklerose obliterans ATE187329T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96830093A EP0793962B1 (de) 1996-03-04 1996-03-04 Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans

Publications (1)

Publication Number Publication Date
ATE187329T1 true ATE187329T1 (de) 1999-12-15

Family

ID=8225823

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96830093T ATE187329T1 (de) 1996-03-04 1996-03-04 Carnitinderivat als arzneimittel zur behandlung von arteriosklerose obliterans

Country Status (13)

Country Link
US (1) US5811457A (de)
EP (1) EP0793962B1 (de)
JP (1) JPH09323927A (de)
KR (1) KR100346883B1 (de)
AT (1) ATE187329T1 (de)
CA (1) CA2198833C (de)
DE (1) DE69605531T2 (de)
DK (1) DK0793962T3 (de)
ES (1) ES2141463T3 (de)
GR (1) GR3032903T3 (de)
PT (1) PT793962E (de)
TW (1) TW349863B (de)
ZA (1) ZA971808B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1295408B1 (it) * 1997-10-03 1999-05-12 Sigma Tau Ind Farmaceuti Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
CA2350071A1 (en) * 1998-11-11 2000-05-18 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis
AU1258699A (en) * 1998-11-11 2000-05-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation
IT1316998B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
ITRM20010708A1 (it) 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
KR20040101521A (ko) * 2002-04-18 2004-12-02 추가이 세이야쿠 가부시키가이샤 혈관 내피의 혈관 장력 조절 기능을 개선하기 위한 의약조성물
US7776913B2 (en) * 2002-12-13 2010-08-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Carnitines for treating or preventing disorders caused by andropause
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
WO2006061341A1 (en) * 2004-12-10 2006-06-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionyl l-carnitine for the preparation of a high-dose medicament for the treatment of peripheral arterial disease
US7560485B2 (en) * 2005-10-04 2009-07-14 Sigma-Tau Industrie Parmaceutiche Riunite S.P.A. Method for treating intermittent claudication comprising the administration of propionyl L-carnitine and a concomitant physical training
EP2353596A1 (de) 2010-02-02 2011-08-10 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Kombinationszusammensetzung mit L-Carnitin oder Proponyl-L-Carnitin als Wirkstoffe zur Vorbeugung oder Behandlung von chronischer Veneninsuffizienz
US20130203848A1 (en) 2010-06-16 2013-08-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compounds useful for increasing neurogenesis in neural tissue
EP2642991A1 (de) 2010-11-22 2013-10-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutisches verfahren zur behandlung der leberschen optikusatrophie
KR20130140100A (ko) 2010-12-09 2013-12-23 씨그마-토 인더스트리에 파마슈티체 리유니테 에스. 피. 에이. 피부 장애 치료용 국소 사용을 위한 조성물
EP2783695A1 (de) 2013-03-28 2014-10-01 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Physiologische Ergänzung oder Medikament zur ophthalmischen Verwendung mit L-Carnitin oder Alkanoyl-L-Carnitinen in Kombination mit Eledoisin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease

Also Published As

Publication number Publication date
MX9701294A (es) 1997-09-30
ZA971808B (en) 1998-07-31
US5811457A (en) 1998-09-22
GR3032903T3 (en) 2000-07-31
DE69605531T2 (de) 2000-05-31
EP0793962B1 (de) 1999-12-08
PT793962E (pt) 2000-05-31
KR100346883B1 (ko) 2003-01-06
KR970064602A (ko) 1997-10-13
DE69605531D1 (de) 2000-01-13
TW349863B (en) 1999-01-11
DK0793962T3 (da) 2000-05-22
EP0793962A1 (de) 1997-09-10
CA2198833C (en) 2003-07-22
ES2141463T3 (es) 2000-03-16
JPH09323927A (ja) 1997-12-16
CA2198833A1 (en) 1997-09-04

Similar Documents

Publication Publication Date Title
ATE187329T1 (de) Carnitinderivat als arzneimittel zur behandlung von arteriosklerose obliterans
DE69831016D1 (de) System zur überwachung und behandlung von schlafstörungen mittels eines transtrachealen katheters
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69213814D1 (de) Melatoninderivate zur Behandlung von Schlafstörungen und zur Pre-Anästhesie
DE69204639D1 (de) Verwendung von Modafinil zur Herstellung eines antiischämischen Arzneimittels.
ATE224714T1 (de) Behandlung von tinnitus mit neuroprotektiven wirkstoffen
ATE141505T1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
ATE212837T1 (de) Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
NO975234D0 (no) Fremgangsmåte for behandling av maniske og bipolare forstyrrelser
DE68911891D1 (de) Verwendung von Acetyl-L-carnitin zur Behandlung von Katarakt, sowie pharmazeutische Zusammensetzungen für eine derartige Behandlung.
ATE119770T1 (de) Verwendung von acetyl l-carnitin zur therapeutischen behandlung von coma.
NO944339L (no) Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser
EP0760659A4 (de) Applikation von alpha-hydroxy-säuren zur behandlung von striae distensae
ATE183088T1 (de) Arzneimittel zur behandlung von hauterkrankungen
EA199900862A1 (ru) Способ лечения сосудистых нарушений
DK0836853T3 (da) Anvendelse af bradykinin-antagonister til fremstilling af lægemidler til behandling og forebyggelse af Alzheimers sygdom
NO953072D0 (no) Anvendelse av inhibitorer av ornitinaminotransferase for fremstilling av et medikament for behandling av Alzheimers sykdom
DE69228235D1 (de) Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung
DE69133298D1 (de) Verwendung von acetylierten Mannanderivaten zur Behandlung von chronischen Atemwegserkrankungen
ATE145133T1 (de) Verwendung von thiol-5-(2-diethyl-aminoethyl)- ester-verbindungen zur herstellung eines arzneimittels zur behandlung der neuromuskuläre inkontinenz
ATE260662T1 (de) Verwendung von olanzapin zur herstellung eines arzneimittels zur neuroprotektion

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification